Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen L Ford

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of the Neurological Sciences|February 17, 2025
Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectoriesCarolyn A Young, David Rog, Basil Sharrack, et al.
Frontiers in Neurology|February 14, 2024
MS care: integrating advanced therapies and holistic managementGavin Giovannoni, Helen L Ford, Klaus Schmierer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2023
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensusPriyanka Iyer, Kate Wiles, Azza Ismail, et al.
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 24, 2022
Measuring coping in multiple sclerosis: The Coping Index-MSCarolyn A Young, Roger J Mills, Dawn Langdon, et al.
European Journal of Neurology|April 3, 2024
Real-world persistence of multiple sclerosis disease-modifying therapiesEmma C Tallantyre, Ruth Dobson, Joseph L J Froud, et al.
BMJ Open|May 17, 2023
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UKBenjamin M Jacobs, Luisa Schalk, Angie Dunne, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of the Neurological Sciences|February 17, 2025
Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectoriesCarolyn A Young, David Rog, Basil Sharrack, et al.
Frontiers in Neurology|February 14, 2024
MS care: integrating advanced therapies and holistic managementGavin Giovannoni, Helen L Ford, Klaus Schmierer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2023
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensusPriyanka Iyer, Kate Wiles, Azza Ismail, et al.
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 24, 2022
Measuring coping in multiple sclerosis: The Coping Index-MSCarolyn A Young, Roger J Mills, Dawn Langdon, et al.
European Journal of Neurology|April 3, 2024
Real-world persistence of multiple sclerosis disease-modifying therapiesEmma C Tallantyre, Ruth Dobson, Joseph L J Froud, et al.
BMJ Open|May 17, 2023
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UKBenjamin M Jacobs, Luisa Schalk, Angie Dunne, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 5